Who Paid My Doc
Matthew Gornet
Chesterfield, MO Medical Doctor
NPI 1962406207 CMS profile 315477
14825 N Outer 40 Rd, Ste 200, Chesterfield, MO 63017
General payments
$245,671
Research payments
$299,163
Ownership & investment interest
$0
Research they led as principal investigator
$267,820
Through program year 2025, Matthew Gornet of Chesterfield, MO is reported in the CMS Open Payments database as having received $245,671 across 163 general payments and $299,163 in research payments paid to them. Separately, studies naming them as principal investigator received $267,820 in research payments, paid to institutions rather than to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
By program year
8 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $36,412 | 42 | |
| 2024 | General | $34,695 | 4 | |
| 2023 | General | $35,386 | 16 | |
| 2022 | General | $34,285 | 19 | |
| 2022 | Research | $299,163 | 12 | |
| 2021 | General | $48,357 | 25 | |
| 2020 | General | $38,506 | 21 | |
| 2019 | General | $18,031 | 36 |
Beside peers
- Matthew Gornet
- Missouri median
- Middle half of Missouri
- National median
In program year 2025, general payments to Matthew Gornet were reported at $36,412. Among 20,470 Missouri profiles paid that year, the median was $164 and the middle half received between $50 and $619.
Show as a table
| Year | Matthew Gornet | Missouri median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $18,031 | $176 | $52–$688 | $163 |
| 2020 | $38,506 | $117 | $36–$411 | $114 |
| 2021 | $48,357 | $136 | $37–$511 | $132 |
| 2022 | $34,285 | $147 | $42–$555 | $149 |
| 2023 | $35,386 | $158 | $46–$594 | $160 |
| 2024 | $34,695 | $159 | $47–$595 | $164 |
| 2025 | $36,412 | $164 | $50–$619 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 4 drugsPart D claims
88
Drug cost
$436
Branded share of claims
0%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Cyclobenzaprine Hcl | Generic | 23 | $179 | |
| Tramadol Hcl | Generic | 15 | $131 | |
| Meloxicam | Generic | 39 | $89 | |
| Prednisone | Generic | 11 | $38 |
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 1,049 Part D prescribers listed as Specialist; they describe a distribution and say nothing about conduct.
Records
175 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Related records
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.